Article

MS Patients Willing to Change Diet, Survey Found

Author(s):

Obesity, along with the composition of the microbiome in the gut, have been suggested as being elements that may contribute to the risk of multiple sclerosis. Patients surveyed said they would be willing to change diet to see if it helped their illness.

Obesity, along with the composition of the microbiome in the gut, have been suggested as being elements that may contribute to the risk of Multiple sclerosis (MS).

In a study presented at the ACTRIMS Forum in New Orleans, LA, University of Virginia researchers J. Nicholas Brenton and colleagues found that MS patients surveyed said overwhelmingly that they would be willing to modify their diet in an attempt to improve or treat their illness.

“Our data demonstrate the feasibility of patient recruitment for future studies assessing therapeutic intervention by way of diet modification for MS”, the team concluded in an abstract presented at the meeting Feb. 19.

The study involved a survey mailed to 604 MS patients at the University of Virginia’s MS clinic.

Of those who received it, 199 subjects returned the survey, of whom 70% were women with a mean disease duration of 12 years

.

Most (71.4%) had relapsing-remitting, MS.

The respondents had generally not tried to change their diets as therapy; only 17% said they had done so.

But 91.5% said they would like to try that therapy and that willingness was not affected by age, gender, disease duration BMI, current diet, MS subtype or other factors.

Asked which diet they wanted to try, most chose paleo (53.8%). High carbohydrate, low salt, modified Atkins were next popular, chosen by a range of 41% to 48% of respondents; vegetarian and vegan options were the least popular.

The authors said the survey’s positive findings should be useful to researchers who want to test the effectiveness of diet-modification in treating MS.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.